IFAA Publishes its year and a half long investigation into the Early Symptoms of Autoimmune Arthritis. This empirical study collected patient-reported early symptoms of Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Ankylosing Spondylitis, and Adult Onset Still's Disease, as experienced in the first 24 months from onset (Early Disease) and cross-referenced the findings with existing symptoms published by the American College of Rheumatology, National Institutes of Health, National Library of Medicine, and Mayo Clinic.
IFAA led a six month investigation into the ethics of step therapy, assisted by bioethicist consultants and Kathleen Arntsen, President & CEO of the Lupus & Allied Diseases Association, Inc. (LADA), as the public policy advisor. IFAA worked diligently to deconstruct step therapy from it's inception, creating mind maps to connect the dots through the decades and eventually identify when and how the protocol began pushing ethical boundaries. The investigation concluded with groundbreaking findings, which were revealed live during a Congressional Briefing in Washington D.C. on November 17th, 2015.
Please review the position paper, "Ethics of Step Therapy and Autoimmune Disease: Next Steps", and if you are a health care stakeholder or public official please sign on to the letter to support modernization of this outdated protocol.
The International Foundation for Autoimmune Arthritis is ranked a Gold Level Participant with GuideStar.
We are a TEAM of passionate patients and patient supporters who united to identify community gaps and solve the problems.
IFAA continuously analyzes the community, through internal investigations and patient to patient communications, to determine the most pressing issues patients face today. Then, using our backgrounds in business and education, we work to develop and implement solutions.
A Community Team (ACT): Redefining Research is designed to gather a global pool of patients, industry and researchers to initiate discussions early in the drug discovery environment so that research ideas and dollars spent will better reflect the patient’s needs. The program enables patients who are usually unable to participate in research discussions due to disease limitations and/or the inability to travel, to contribute through a flexible virtual platform. This pilot project will initially focus on patients with Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), and/or Axial Spondylitis (AxSpA) and the process will be 'blueprinted' so it can be used for future expansion with other diseases. LEARN MORE
Copyright 2016. All rights reserved. Information on this site is intended for informational purposes only Our foundation does not engage in the practice of medicine. Please consult a physician to obtain personal healthcare and treatment options. Tax ID: 27-1214308